The protective role of pre-morbid type 2 diabetes in patients with amyotrophic lateral sclerosis: a center-based survey in China

References

• Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.
   PubMed Web of Science ®Google Scholar
• Steinke J, Tyler HR. The association of amyotrophic lateral sclerosis (motor neuron disease) and carbohydrate intolerance, a clinical study. Metabolism. 1964;13:1376–81.
   PubMed Web of Science ®Google Scholar
• Perurena OH, Festoff BW. Reduction in insulin receptors in amyotrophic lateral sclerosis correlates with reduced insulin sensitivity. Neurology. 1987;37:1375–9.
   PubMed Web of Science ®Google Scholar
• Pradat PF, Bruneteau G, Gordon PH, Dupuis L, Bonnefont-Rousselot D, Simon D, et al. Impaired glucose tolerance in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;4:166–71.
   Web of Science ®Google Scholar
• Mariosa D, Kamel F, Bellocco R, Ye W, Fang F. Association between diabetes and amyotrophic lateral sclerosis in Sweden. Eur J Neurol. 2015;22:1436–42.
   PubMed Web of Science ®Google Scholar
• Kioumourtzoglou MA, Rotem RS, Seals RM, Gredal O, Hansen J, Weisskopf MG. Diabetes, obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. JAMA Neurol. 2015;72:905–11.
   PubMed Web of Science ®Google Scholar
• D’Ovidio F, D’Errico A, Carna P, Calvo A, Costa G, Chio A. The role of pre-morbid diabetes on developing amyotrophic lateral sclerosis. Eur J Neurol. 2018;25:164–70.
   PubMed Web of Science ®Google Scholar
• Sun Y, Lu CJ, Chen RC, Hou WH, Li CY. Risk of amyotrophic lateral sclerosis in patients with diabetes: a nationwide population-based cohort study. J Epidemiol. 2015;25:445–51.
   PubMed Web of Science ®Google Scholar
• Jawaid A, Salamone AR, Strutt AM, Murthy SB, Wheaton M, McDowell EJ, et al. ALS disease onset may occur later in patients with pre-morbid diabetes. Eur J Neurol. 2010;17:733–9.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Hyman T, Shui A, Allred P, Harms M, Liu J, et al. Pre-morbid type 2 diabetes is not a prognostic factor in amyotrophic lateral sclerosis. Muscle Nerve. 2015;52:339–43.
   PubMed Web of Science ®Google Scholar
• Jawaid A, Schulz PE. Pre-morbid type 2 diabetes as a prognostic factor in amyotrophic lateral sclerosis. Muscle Nerve. 2015;52:690–1.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhang B, Chen R, Tang L, Liu R, Yang Y, et al. Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China. J Neurol Neurosurg Psychiatry. 2015;86:1075–81.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
   PubMed Web of Science ®Google Scholar
• Kim DH, Pickhardt PJ, Taylor AJ, Leung WK, Winter TC, Hinshaw JL, et al. CT colonography versus colonoscopy for the detection of advanced neoplasia. N Engl J Med. 2007;357:1403–12.
   PubMed Web of Science ®Google Scholar
• Austin PC. Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: a systematic review and suggestions for improvement. J Thoracic Cardiovasc Surg. 2007;134:1128–35.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al. Prevalence and control of diabetes in Chinese adults. J Am Med Assoc. 2013;310:948–59.
   PubMed Web of Science ®Google Scholar
• Kihira T, Yoshida S, Okamoto K, Kazimoto Y, Ookawa M, Hama K, et al. Survival rate of patients with amyotrophic lateral sclerosis in Wakayama Prefecture, Japan, 1966 to 2005. J Neurol Sci. 2008;268:95–101.
   PubMed Web of Science ®Google Scholar
• Chio A, Mora G, Calvo A, Mazzini L, Bottacchi E, Mutani R. Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology. 2009;72:725–31.
   PubMed Web of Science ®Google Scholar
• Logroscino G, Traynor BJ, Hardiman O, Chiò A, Mitchell D, Swingler RJ, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81:385–90.
   PubMed Web of Science ®Google Scholar
• Rosenbohm A, Liu M, Nagel G, Peter RS, Cui B, Li X, et al. Phenotypic differences of amyotrophic lateral sclerosis (ALS) in China and Germany. J Neurol. 2018;265:774–82.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9:617–28.
   PubMed Web of Science ®Google Scholar
• Liu MS, Cui LY, Fan DS. Age at onset of amyotrophic lateral sclerosis in China. Acta Neurol Scand. 2014;129:163–7.
   PubMed Web of Science ®Google Scholar
• He J, Tang L, Benyamin B, Shah S, Hemani G, Liu R, et al. C9orf72 hexanucleotide repeat expansions in Chinese sporadic amyotrophic lateral sclerosis. Neurobiology of Aging. 2015;36:2660.e1–8.
   Web of Science ®Google Scholar
• Ogaki K, Li Y, Atsuta N, Tomiyama H, Funayama M, Watanabe H, et al. Analysis of C9orf72 repeat expansion in 563 Japanese patients with amyotrophic lateral sclerosis. Neurobiology of Aging. 2012;33:2527.e11–6.
   PubMed Web of Science ®Google Scholar
• Moglia C, Calvo A, Canosa A, Bertuzzo D, Cugnasco P, Solero L, et al. Influence of arterial hypertension, type 2 diabetes and cardiovascular risk factors on ALS outcome: a population-based study. Amyotrop Lateral Scler Frontotemporal Degener. 2017;18:590–7.
   PubMed Web of Science ®Google Scholar
• Vercruysse P, Vieau D, Blum D, Petersen A, Dupuis L. Hypothalamic alterations in Neurodegenerative diseases and their relation to abnormal energy metabolism. Front Mol Neurosci. 2018;11:2.
   PubMed Web of Science ®Google Scholar
• Vercruysse P, Sinniger J, El Oussini H, Scekic-Zahirovic J, Dieterle S, Dengler R, et al. Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis. Brain. 2016;139:1106–22.
   PubMed Web of Science ®Google Scholar
• Ahmed RM, Irish M, Piguet O, Halliday GM, Ittner LM, Farooqi S, et al. Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolism. Lancet Neurol. 2016;15:332–42.
   PubMed Web of Science ®Google Scholar
• Ahmed RM, Caga J, Devenney E, Hsieh S, Bartley L, Highton-Williamson E, et al. Cognition and eating behavior in amyotrophic lateral sclerosis: effect on survival. J Neurol. 2016;263:1593–603.
   PubMed Web of Science ®Google Scholar
• Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease–is this type 3 diabetes? J Alzheimers Dis. 2005;7:63–80.
   PubMed Web of Science ®Google Scholar
• Hao K, Di Narzo AF, Ho L, Luo W, Li S, Chen R, et al. Shared genetic etiology underlying Alzheimer’s disease and type 2 diabetes. Mol Aspects Med. 2015;43-44:66–76.
   PubMed Web of Science ®Google Scholar
• Jawaid A, Abid A, Schulz PE. Diabetes and amyotrophic lateral sclerosis: time to bridge the gap between the bench and the bedside. Eur J Neurol. 2018;25:3–4.
   PubMed Web of Science ®Google Scholar
• Bouteloup C, Desport JC, Clavelou P, Guy N, Derumeaux-Burel H, Ferrier A, et al. Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol. 2009;256:1236–42.
   PubMed Web of Science ®Google Scholar
• Steyn FJ, Ioannides ZA, van Eijk RPA, Heggie S, Thorpe KA, Ceslis A, et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J Neurol Neurosurg Psychiatry. 2018;89:1016–23.
   PubMed Web of Science ®Google Scholar
• Nicolakakis N, Aboulkassim T, Ongali B, Lecrux C, Fernandes P, Rosa-Neto P, et al. Complete rescue of cerebrovascular function in aged Alzheimer’s disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J Neurosci. 2008;28:9287–96.
   PubMed Web of Science ®Google Scholar
• Chaturvedi RK, Beal MF. PPAR: a therapeutic target in Parkinson’s disease. J Neurochem. 2008;106:506–18.
   PubMed Web of Science ®Google Scholar
• Ma TC, Buescher JL, Oatis B, Funk JA, Nash AJ, Carrier RL, et al. Metformin therapy in a transgenic mouse model of Huntington’s disease. Neurosci Letters. 2007;411:98–103.
   PubMed Web of Science ®Google Scholar
• Kaneb HM, Sharp PS, Rahmani-Kondori N, Wells DJ. Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice. PLoS One. 2011;6:e24189.
   PubMed Web of Science ®Google Scholar
• Dupuis L, Dengler R, Heneka MT, Meyer T, Zierz S, Kassubek J, et al. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One. 2012;7:e37885.
   PubMed Web of Science ®Google Scholar
• Logroscino G. Motor neuron disease: are diabetes and amyotrophic lateral sclerosis related? Nat Rev Neurol. 2015;11:488–90.
   PubMed Web of Science ®Google Scholar